RATIONALE: α1-Antitrypsin (A1AT) was identified as a plasma protease inhibitor; however, it is now recognized as a multifunctional protein that modulates immunity, inflammation, proteostasis, apoptosis, and cellular senescence. Like A1AT, protein phosphatase 2A (PP2A), a major serine-threonine phosphatase, regulates similar biologic processes and plays a key role in chronic obstructive pulmonary disease. OBJECTIVES: Given their common effects, this study investigated whether A1AT acts via PP2A to alter tumor necrosis factor (TNF) signaling, inflammation, and proteolytic responses in this disease. METHODS: PP2A activity was measured in peripheral blood neutrophils from A1AT-deficient (PiZZ) and healthy (PiMM) individuals and in alveolar macrophages from normal (60 mg/kg) and high-dose (120 mg/kg) A1AT-treated PiZZ subjects. PP2A activation was assessed in human neutrophils, airway epithelial cells, and peripheral blood monocytes treated with plasma purified A1AT protein. Similarly, lung PP2A activity was measured in mice administered intranasal A1AT. PP2A was silenced in lung epithelial cells treated with A1AT and matrix metalloproteinase and cytokine production was then measured following TNF-α stimulation. MEASUREMENTS AND MAIN RESULTS: PP2A was significantly lower in neutrophils isolated from PiZZ compared with PiMM subjects. A1AT protein activated PP2A in human alveolar macrophages, monocytes, neutrophils, airway epithelial cells, and in mouse lungs. This activation required functionally active A1AT protein and protein tyrosine phosphatase 1B expression. A1AT treatment acted via PP2A to prevent p38 and IκBα phosphorylation and matrix metalloproteinase and cytokine induction in TNF-α-stimulated epithelial cells. CONCLUSIONS: Together, these data indicate that A1AT modulates PP2A to counter inflammatory and proteolytic responses induced by TNF signaling in the lung.
RATIONALE: α1-Antitrypsin (A1AT) was identified as a plasma protease inhibitor; however, it is now recognized as a multifunctional protein that modulates immunity, inflammation, proteostasis, apoptosis, and cellular senescence. Like A1AT, protein phosphatase 2A (PP2A), a major serine-threonine phosphatase, regulates similar biologic processes and plays a key role in chronic obstructive pulmonary disease. OBJECTIVES: Given their common effects, this study investigated whether A1AT acts via PP2A to alter tumor necrosis factor (TNF) signaling, inflammation, and proteolytic responses in this disease. METHODS:PP2A activity was measured in peripheral blood neutrophils from A1AT-deficient (PiZZ) and healthy (PiMM) individuals and in alveolar macrophages from normal (60 mg/kg) and high-dose (120 mg/kg) A1AT-treated PiZZ subjects. PP2A activation was assessed in human neutrophils, airway epithelial cells, and peripheral blood monocytes treated with plasma purified A1AT protein. Similarly, lung PP2A activity was measured in mice administered intranasal A1AT. PP2A was silenced in lung epithelial cells treated with A1AT and matrix metalloproteinase and cytokine production was then measured following TNF-α stimulation. MEASUREMENTS AND MAIN RESULTS:PP2A was significantly lower in neutrophils isolated from PiZZ compared with PiMM subjects. A1AT protein activated PP2A in human alveolar macrophages, monocytes, neutrophils, airway epithelial cells, and in mouse lungs. This activation required functionally active A1AT protein and protein tyrosine phosphatase 1B expression. A1AT treatment acted via PP2A to prevent p38 and IκBα phosphorylation and matrix metalloproteinase and cytokine induction in TNF-α-stimulated epithelial cells. CONCLUSIONS: Together, these data indicate that A1AT modulates PP2A to counter inflammatory and proteolytic responses induced by TNF signaling in the lung.
Authors: Michael A Campos; Friedrich Kueppers; James M Stocks; Charlie Strange; Junliang Chen; Rhonda Griffin; Laurene Wang-Smith; Mark L Brantly Journal: COPD Date: 2013-07-17 Impact factor: 2.409
Authors: J A Carlson; B B Rogers; R N Sifers; M J Finegold; S M Clift; F J DeMayo; D W Bullock; S L Woo Journal: J Clin Invest Date: 1989-04 Impact factor: 14.808
Authors: Irina Petrache; Iwona Fijalkowska; Terry R Medler; Jarrett Skirball; Pedro Cruz; Lijie Zhen; Horia I Petrache; Terence R Flotte; Rubin M Tuder Journal: Am J Pathol Date: 2006-10 Impact factor: 4.307
Authors: Alison M Wallace; Andrew Hardigan; Patrick Geraghty; Shaneeza Salim; Adam Gaffney; Jincy Thankachen; Leo Arellanos; Jeanine M D'Armiento; Robert F Foronjy Journal: Toxicol Sci Date: 2012-01-05 Impact factor: 4.849
Authors: Ann-Sofi Härmälä-Braskén; Andrey Mikhailov; Thomas S Söderström; Annika Meinander; Tim H Holmström; Zahi Damuni; John E Eriksson Journal: Oncogene Date: 2003-10-23 Impact factor: 9.867
Authors: Katie M Stiles; Dolan Sondhi; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Ronald G Crystal Journal: Chronic Obstr Pulm Dis Date: 2018-08-17
Authors: Patrick Geraghty; Nathalie Baumlin; Matthias A Salathe; Robert F Foronjy; Jeanine M D'Armiento Journal: Mediators Inflamm Date: 2016-12-13 Impact factor: 4.711
Authors: Yotam Lior; Mariana Zaretsky; David E Ochayon; Diana Lotysh; Boris M Baranovski; Ronen Schuster; Ofer Guttman; Amir Aharoni; Eli C Lewis Journal: Front Immunol Date: 2018-05-01 Impact factor: 7.561
Authors: Declan F Doherty; Sridesh Nath; Justin Poon; Robert F Foronjy; Michael Ohlmeyer; Abdoulaye J Dabo; Matthias Salathe; Mark Birrell; Maria Belvisi; Nathalie Baumlin; Michael D Kim; Sinéad Weldon; Clifford Taggart; Patrick Geraghty Journal: Am J Respir Crit Care Med Date: 2019-07-01 Impact factor: 21.405